Research ArticleOriginal Article
Open Access

Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus

Xiao-Li Wang, Fang Ye, Jun Li, Ling-Yun Zhu, Gang Feng, Xiang-Yun Chang and Kan Sun
Saudi Medical Journal January 2016, 37 (1) 48-54; DOI: https://doi.org/10.15537/smj.2016.1.12035

References

  1. ↵
    1. Xu Y,
    2. Wang L,
    3. He J,
    4. Bi Y,
    5. Li M,
    6. Wang T,
    7. et al.
    (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310:948–959.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Cho YM,
    2. Fujita Y,
    3. Kieffer TJ
    (2014) Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physiol 76:535–559.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Drucker DJ
    (2013) Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62:3316–3323.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Seino Y,
    2. Yabe D
    (2013) Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 4:108–130.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Ten Kulve JS,
    2. Veltman DJ,
    3. van Bloemendaal L,
    4. Barkhof F,
    5. Deacon CF,
    6. Holst JJ,
    7. et al.
    (2015) Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia 58:2688–2698.
    OpenUrlCrossRefPubMed
    1. Van Bloemendaal L,
    2. Ten Kulve JS,
    3. la Fleur SE,
    4. Ijzerman RG,
    5. Diamant M
    (2014) Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 221:T1–16.
    OpenUrlAbstract/FREE Full Text
    1. Lee YS,
    2. Jun HS
    (2014) Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 63:9–19.
    OpenUrlCrossRefPubMed
    1. Dailey MJ,
    2. Moran TH
    (2013) Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 24:85–91.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Campbell JE,
    2. Drucker DJ
    (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17:819–837.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Toft-Nielsen MB,
    2. Damholt MB,
    3. Madsbad S,
    4. Hilsted LM,
    5. Hughes TE,
    6. Michelsen BK,
    7. et al.
    (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Calanna S,
    2. Christensen M,
    3. Holst JJ,
    4. Laferrere B,
    5. Gluud LL,
    6. Vilsboll T,
    7. et al.
    (2013) Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 56:965–972.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Vollmer K,
    2. Holst JJ,
    3. Baller B,
    4. Ellrichmann M,
    5. Nauck MA,
    6. Schmidt WE,
    7. et al.
    (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678–687.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Alberti KG,
    2. Zimmet PZ
    (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Matthews DR,
    2. Hosker JP,
    3. Rudenski AS,
    4. Naylor BA,
    5. Treacher DF,
    6. Turner RC
    (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Matsuda M,
    2. DeFronzo RA
    (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Gutt M,
    2. Davis CL,
    3. Spitzer SB,
    4. Llabre MM,
    5. Kumar M,
    6. Czarnecki EM,
    7. et al.
    (2000) Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 47:177–184.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Zhang F,
    2. Tang X,
    3. Cao H,
    4. Lu Q,
    5. Li N,
    6. Liu Y,
    7. et al.
    (2012) Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci 9:574–581.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Yabe D,
    2. Kuroe A,
    3. Watanabe K,
    4. Iwasaki M,
    5. Hamasaki A,
    6. Hamamoto Y,
    7. et al.
    (2015) Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. J Diabetes Complications 29:413–421.
    OpenUrlCrossRefPubMed
    1. Brown RJ,
    2. Walter M,
    3. Rother KI
    (2012) Effects of diet soda on gut hormones in youths with diabetes. Diabetes Care 35:959–964.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Nauck MA,
    2. Vardarli I,
    3. Deacon CF,
    4. Holst JJ,
    5. Meier JJ
    (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54:10–18.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Wang X,
    2. Liu H,
    3. Chen J,
    4. Li Y,
    5. Qu S
    (2015) Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. Int J Endocrinol 2015, 651757.
  22. ↵
    1. Beysen C,
    2. Murphy EJ,
    3. Deines K,
    4. Chan M,
    5. Tsang E,
    6. Glass A,
    7. et al.
    (2012) Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 55:432–442.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Geloneze B,
    2. de Oliveira Mda S,
    3. Vasques AC,
    4. Novaes FS,
    5. Pareja JC,
    6. Tambascia MA
    (2014) Impaired incretin secretion and pancreatic dysfunction with older age and diabetes. Metabolism 63:922–929.
    OpenUrl
  24. ↵
    1. Shu L,
    2. Matveyenko AV,
    3. Kerr-Conte J,
    4. Cho JH,
    5. McIntosh CH,
    6. Maedler K
    (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 18:2388–2399.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Müssig K,
    2. Staiger H,
    3. Machicao F,
    4. Kirchhoff K,
    5. Guthoff M,
    6. Schäfer SA,
    7. et al.
    (2009) Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes 58:1715–1720.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Sleddering MA,
    2. Bakker LE,
    3. Janssen LG,
    4. Meinders AE,
    5. Jazet IM
    (2014) Higher insulin and glucagon-like peptide-1 (GLP-1) levels in healthy, young South Asians as compared to Caucasians during an oral glucose tolerance test. Metabolism 63:226–232.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Bagger JI,
    2. Knop FK,
    3. Lund A,
    4. Vestergaard H,
    5. Holst JJ,
    6. Vilsboll T
    (2011) Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96:737–745.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section